CN108264535A - 一种抗抑郁化合物及其制备方法和应用 - Google Patents
一种抗抑郁化合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN108264535A CN108264535A CN201611260514.6A CN201611260514A CN108264535A CN 108264535 A CN108264535 A CN 108264535A CN 201611260514 A CN201611260514 A CN 201611260514A CN 108264535 A CN108264535 A CN 108264535A
- Authority
- CN
- China
- Prior art keywords
- substitution
- alkyl
- aryl
- compound
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(C1)C(C)(C(*)*)C2C(*)C(*)(*)*C1C2 Chemical compound CC(C1)C(C)(C(*)*)C2C(*)C(*)(*)*C1C2 0.000 description 7
- VULHYRAYXYTONQ-UHFFFAOYSA-N C=Nc1ccccc1 Chemical compound C=Nc1ccccc1 VULHYRAYXYTONQ-UHFFFAOYSA-N 0.000 description 1
- BVGFNLOTMRPWBL-KUOTWQNZSA-N CC(C)CC[C@@]([C@H]1C)(O)O[C@@H](C2)C1[C@@](C)(CC1)[C@@H]2[C@H](CC2)[C@H]1C(C)(CC1)[C@H]2CC1NC=O Chemical compound CC(C)CC[C@@]([C@H]1C)(O)O[C@@H](C2)C1[C@@](C)(CC1)[C@@H]2[C@H](CC2)[C@H]1C(C)(CC1)[C@H]2CC1NC=O BVGFNLOTMRPWBL-KUOTWQNZSA-N 0.000 description 1
- RJWLLQWLBMJCFD-UHFFFAOYSA-N CN(CC1)CCN1N Chemical compound CN(CC1)CCN1N RJWLLQWLBMJCFD-UHFFFAOYSA-N 0.000 description 1
- KQDFSRGKYCPPGX-UHFFFAOYSA-N CN(CC1)CCN1NC=O Chemical compound CN(CC1)CCN1NC=O KQDFSRGKYCPPGX-UHFFFAOYSA-N 0.000 description 1
- NNGAQKAUYDTUQR-UHFFFAOYSA-N N=C1CCCCC1 Chemical compound N=C1CCCCC1 NNGAQKAUYDTUQR-UHFFFAOYSA-N 0.000 description 1
- LUBJCRLGQSPQNN-UHFFFAOYSA-N NC(Nc1ccccc1)=O Chemical compound NC(Nc1ccccc1)=O LUBJCRLGQSPQNN-UHFFFAOYSA-N 0.000 description 1
- PAFZNILMFXTMIY-UHFFFAOYSA-N NC1CCCCC1 Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611260514.6A CN108264535A (zh) | 2016-12-30 | 2016-12-30 | 一种抗抑郁化合物及其制备方法和应用 |
| PCT/CN2017/120134 WO2018121770A1 (zh) | 2016-12-30 | 2017-12-29 | 一种抗抑郁化合物及其制备方法和应用 |
| EP17889516.5A EP3564253B1 (en) | 2016-12-30 | 2017-12-29 | Antidepressant compound and preparation method and application thereof |
| CN201780081277.3A CN110121502B (zh) | 2016-12-30 | 2017-12-29 | 一种抗抑郁化合物及其制备方法和应用 |
| JP2019536014A JP6901569B2 (ja) | 2016-12-30 | 2017-12-29 | 抗うつ化合物およびその製造方法と使用 |
| US16/474,668 US11142543B2 (en) | 2016-12-30 | 2017-12-29 | Antidepressant compound and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611260514.6A CN108264535A (zh) | 2016-12-30 | 2016-12-30 | 一种抗抑郁化合物及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108264535A true CN108264535A (zh) | 2018-07-10 |
Family
ID=62707894
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611260514.6A Pending CN108264535A (zh) | 2016-12-30 | 2016-12-30 | 一种抗抑郁化合物及其制备方法和应用 |
| CN201780081277.3A Active CN110121502B (zh) | 2016-12-30 | 2017-12-29 | 一种抗抑郁化合物及其制备方法和应用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780081277.3A Active CN110121502B (zh) | 2016-12-30 | 2017-12-29 | 一种抗抑郁化合物及其制备方法和应用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11142543B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3564253B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP6901569B2 (cg-RX-API-DMAC10.html) |
| CN (2) | CN108264535A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018121770A1 (cg-RX-API-DMAC10.html) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109053854A (zh) * | 2018-09-29 | 2018-12-21 | 莱芜清博汇能医药科技有限公司 | 基于知母菝契皂苷元结构的衍生物、药物组合物及其应用 |
| CN109206472A (zh) * | 2018-09-27 | 2019-01-15 | 华东理工大学 | 薯蓣皂苷元衍生物、其药物组合物及其应用 |
| CN109988218A (zh) * | 2017-12-29 | 2019-07-09 | 中国科学院上海药物研究所 | 一种菝葜皂苷元衍生物及其制备方法和应用 |
| CN113831382A (zh) * | 2020-06-24 | 2021-12-24 | 中国科学院上海药物研究所 | 一种甾体化合物 |
| CN116621912A (zh) * | 2022-02-18 | 2023-08-22 | 北京清博汇能医药科技有限公司 | 基于菝契皂苷元结构的衍生物及其药物组合物的用途 |
| WO2023155757A1 (zh) * | 2022-02-18 | 2023-08-24 | 北京清博汇能医药科技有限公司 | 基于菝契皂苷元结构的衍生物及其药物组合物的用途 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019129176A1 (zh) * | 2017-12-29 | 2019-07-04 | 中国科学院上海药物研究所 | 一种菝葜皂苷元衍生物及其制备方法和应用 |
| CN112142817B (zh) * | 2019-06-26 | 2021-10-22 | 中国科学院上海药物研究所 | 一种抗抑郁甾体化合物 |
| CN113831381A (zh) * | 2020-06-24 | 2021-12-24 | 中国科学院上海药物研究所 | 一种用于治疗抑郁症的甾体化合物 |
| CN113292629B (zh) * | 2021-06-21 | 2022-04-26 | 西南民族大学 | 薯蓣皂苷元羟肟酸类衍生物及其制备方法和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9923077D0 (en) | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
| GB0000228D0 (en) | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
| PL213697B1 (pl) * | 2002-03-27 | 2013-04-30 | Phytopharm Plc | Substancje czynne do stosowania w leczeniu chorób, zwlaszcza chorób neurodegeneracyjnych |
| WO2005051381A1 (en) * | 2003-11-26 | 2005-06-09 | Biovitrum Ab | Substituted urea-octatydroindols as antagonists of melanin concentrating hormone receptor 1 (MCH1R) |
| WO2005051380A1 (en) | 2003-11-26 | 2005-06-09 | Biovitrum Ab | Substituted urea-octahydroindols as antagonists of melanin concentrating hormone receptor 1 (mch1r) |
| US20050245495A1 (en) * | 2004-04-07 | 2005-11-03 | Chen Zhao | Azacyclosteroid histamine-3 receptor ligands |
| US7879834B2 (en) | 2004-08-19 | 2011-02-01 | Vertex Pharmaceuticals Incorporated | Spiroindoline modulators of muscarinic receptors |
| CN101214253B (zh) | 2008-01-07 | 2011-09-21 | 中国人民解放军第二军医大学 | 知母皂苷b-ⅱ用于制备抗抑郁产品的用途 |
| WO2009109477A1 (en) | 2008-03-05 | 2009-09-11 | F. Hoffmann-La Roche Ag | 2-aminoquinolines |
| CN101768202B (zh) | 2009-02-18 | 2013-10-30 | 沈阳药科大学 | 知母中菝葜皂苷元及其衍生物的制备方法及其医药新用途 |
| CN102924559B (zh) * | 2012-11-16 | 2015-10-28 | 沈阳药科大学 | 菝葜皂苷元衍生物及其制备和应用 |
| WO2015163318A1 (ja) * | 2014-04-25 | 2015-10-29 | レジリオ株式会社 | アルツハイマー病の治療剤を含む、神経細胞の軸索の機能不全が関与する疾患の治療剤 |
| WO2019129176A1 (zh) | 2017-12-29 | 2019-07-04 | 中国科学院上海药物研究所 | 一种菝葜皂苷元衍生物及其制备方法和应用 |
-
2016
- 2016-12-30 CN CN201611260514.6A patent/CN108264535A/zh active Pending
-
2017
- 2017-12-29 US US16/474,668 patent/US11142543B2/en active Active
- 2017-12-29 CN CN201780081277.3A patent/CN110121502B/zh active Active
- 2017-12-29 WO PCT/CN2017/120134 patent/WO2018121770A1/zh not_active Ceased
- 2017-12-29 EP EP17889516.5A patent/EP3564253B1/en active Active
- 2017-12-29 JP JP2019536014A patent/JP6901569B2/ja active Active
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109988218A (zh) * | 2017-12-29 | 2019-07-09 | 中国科学院上海药物研究所 | 一种菝葜皂苷元衍生物及其制备方法和应用 |
| CN109988218B (zh) * | 2017-12-29 | 2022-11-25 | 中国科学院上海药物研究所 | 一种菝葜皂苷元衍生物及其制备方法和应用 |
| CN109206472A (zh) * | 2018-09-27 | 2019-01-15 | 华东理工大学 | 薯蓣皂苷元衍生物、其药物组合物及其应用 |
| KR102655595B1 (ko) * | 2018-09-29 | 2024-04-08 | 피토벤트 바이오파마 | 지모의 사르사사포게닌 구조를 기반으로 하는 유도체, 약물 조성물 및 그의 용도 |
| WO2020062883A1 (zh) * | 2018-09-29 | 2020-04-02 | 深圳清博汇能医药科技有限公司 | 基于知母菝契皂苷元结构的衍生物、药物组合物及其应用 |
| CN109053854B (zh) * | 2018-09-29 | 2021-05-14 | 深圳清博汇能医药科技有限公司 | 基于知母菝契皂苷元结构的衍生物、药物组合物及其应用 |
| KR20210096074A (ko) * | 2018-09-29 | 2021-08-04 | 피토벤트 바이오파마 | 지모의 사르사사포게닌 구조를 기반으로 하는 유도체, 약물 조성물 및 그의 용도 |
| CN109053854A (zh) * | 2018-09-29 | 2018-12-21 | 莱芜清博汇能医药科技有限公司 | 基于知母菝契皂苷元结构的衍生物、药物组合物及其应用 |
| AU2019345516B2 (en) * | 2018-09-29 | 2022-10-20 | Phytovent Biopharma | Derivative of sarsasapogenin, pharmaceutical composition and use thereof |
| US12448410B2 (en) | 2018-09-29 | 2025-10-21 | Phytovent Biopharma | Derivative of sarsasapogenin, pharmaceutical composition and use thereof |
| CN113831382A (zh) * | 2020-06-24 | 2021-12-24 | 中国科学院上海药物研究所 | 一种甾体化合物 |
| WO2023155757A1 (zh) * | 2022-02-18 | 2023-08-24 | 北京清博汇能医药科技有限公司 | 基于菝契皂苷元结构的衍生物及其药物组合物的用途 |
| CN116621912A (zh) * | 2022-02-18 | 2023-08-22 | 北京清博汇能医药科技有限公司 | 基于菝契皂苷元结构的衍生物及其药物组合物的用途 |
| CN116621912B (zh) * | 2022-02-18 | 2026-07-10 | 北京清博汇能医药科技有限公司 | 基于菝契皂苷元结构的衍生物及其药物组合物的用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018121770A1 (zh) | 2018-07-05 |
| CN110121502B (zh) | 2022-09-23 |
| JP2020503341A (ja) | 2020-01-30 |
| JP6901569B2 (ja) | 2021-07-14 |
| EP3564253A1 (en) | 2019-11-06 |
| EP3564253A4 (en) | 2020-07-29 |
| US20200385418A1 (en) | 2020-12-10 |
| US11142543B2 (en) | 2021-10-12 |
| CN110121502A (zh) | 2019-08-13 |
| EP3564253B1 (en) | 2024-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3564253B1 (en) | Antidepressant compound and preparation method and application thereof | |
| US11149006B2 (en) | Compounds as neurokinin-1 receptor antagonists and uses thereof | |
| TWI357327B (en) | Pyrazoline compounds | |
| ES3014632T3 (en) | Cannabinoid derivatives | |
| CN108366996A (zh) | 四氢-1H-吡啶[3,4-b]吲哚类抗雌激素药物 | |
| CN103130737B (zh) | 环己烷胺类化合物及其作为抗精神分裂症药物的应用 | |
| TWI579277B (zh) | 取代桂皮醯胺衍生物、其製備方法、其應用及醫藥組成物 | |
| JP5701213B2 (ja) | 新規なドーパミンd3受容体リガンド、その調製及び使用 | |
| JP2012505165A5 (cg-RX-API-DMAC10.html) | ||
| TW202340145A (zh) | 氘化有機化合物及其用途 | |
| CN105777706B (zh) | 一种3-[(苯并[d][1, 3]二氧戊环-4-基)-氧基]-3-芳基丙胺类化合物及其应用 | |
| EA019360B1 (ru) | Алканолпиперазиновые производные бензотиофена и их применение в качестве антидепрессанта | |
| WO2019129176A1 (zh) | 一种菝葜皂苷元衍生物及其制备方法和应用 | |
| CN103360342B (zh) | 3-氰基苯胺烷基芳基哌嗪衍生物及在制备药物中的应用 | |
| CN109988218B (zh) | 一种菝葜皂苷元衍生物及其制备方法和应用 | |
| CN113272315B (zh) | 一类类固醇化合物及其用途 | |
| CA3239518A1 (en) | Benzofuran salt morphic forms and mixtures for the treatment of mental disorders or mental enhancement | |
| CN119504546B (zh) | 内酰胺环类化合物及其用途 | |
| CN112142817B (zh) | 一种抗抑郁甾体化合物 | |
| TW200538099A (en) | Fused ring NK1 antagonists | |
| CN107586281A (zh) | 芳烷杂环类衍生物及其在多靶点抗抑郁症中的应用 | |
| KR102906581B1 (ko) | 올레아난 신남아미드 유도체 및 이의 제조 방법과 용도 | |
| KR102629506B1 (ko) | 피페라진-퀴놀린 유도체로서 2-에틸-5-(4-메틸-피페라진-1-일)-1-(나프탈렌-2-설포닐)-2,3-디하이드로-1h-퀴놀린-4-온의 제조방법 | |
| TW201026691A (en) | Biaryl spiroaminooxazoline analogues as alpha2C adrenergic receptor modulators | |
| CN115785094B (zh) | 苄基取代α-咔啉化合物或其药用盐、其药物组合物及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180710 |
|
| WD01 | Invention patent application deemed withdrawn after publication |